HYGROTON
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYGROTON is an oral tablet small-molecule drug approved in 1960 by Sanofi. The generic name and specific mechanism of action are not currently available in this dataset. This is a legacy NDA product with significant historical presence in the U.S. market.
LOE Approaching
Product is in LOE-approaching phase with modest competitive pressure (30%), suggesting a shrinking commercial team focused on maintenance and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYGROTON offers limited career growth given its mature lifecycle and zero linked job openings. This is a maintenance role suited to professionals transitioning from growth-stage products or preparing for generic management expertise.
Brand ManagerField Sales
Worked on HYGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.